WallStreetZenWallStreetZen

NASDAQ: MREO
Mereo Biopharma Group PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MREO

Based on 5 analysts offering 12 month price targets for Mereo Biopharma Group PLC

Min Forecast
$7.00+204.35%
Avg Forecast
$7.60+230.43%
Max Forecast
$10.00+334.78%

Should I buy or sell MREO stock?

Based on 5 analysts offering ratings for Mereo Biopharma Group PLC.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MREO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MREO as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their MREO stock forecasts and price targets.

MREO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-09
lockedlocked$00.00+00.00%2025-03-27
lockedlocked$00.00+00.00%2025-03-18
lockedlocked$00.00+00.00%2024-12-24
lockedlocked$00.00+00.00%2024-12-06

1 of 1

Forecast return on equity

Is MREO forecast to generate an efficient return?

Company
234.71%
Industry
147.71%
Market
81.76%
MREO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MREO forecast to generate an efficient return on assets?

Company
187.33%
Industry
35.52%
MREO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MREO earnings per share forecast

What is MREO's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.04
Avg 2 year Forecast
$0.00
Avg 3 year Forecast
-$0.01

MREO revenue forecast

What is MREO's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$83.5M
Avg 2 year Forecast
$65.9M
Avg 3 year Forecast
$123.8M

MREO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MREO$2.30$7.60+230.43%Strong Buy
MAZE$8.41$25.67+205.20%Strong Buy
RAPP$10.15$28.00+175.86%Buy
SANA$1.65$7.67+364.67%Strong Buy
ZBIO$8.92$32.25+261.55%Strong Buy
View Top Biotech Stocks

Mereo Biopharma Group Stock Forecast FAQ

Is Mereo Biopharma Group Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: MREO) stock is to Strong Buy MREO stock.

Out of 5 analysts, 3 (60%) are recommending MREO as a Strong Buy, 2 (40%) are recommending MREO as a Buy, 0 (0%) are recommending MREO as a Hold, 0 (0%) are recommending MREO as a Sell, and 0 (0%) are recommending MREO as a Strong Sell.

If you're new to stock investing, here's how to buy Mereo Biopharma Group stock.

What is MREO's earnings growth forecast for 2025-2027?

(NASDAQ: MREO) Mereo Biopharma Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Mereo Biopharma Group's earnings in 2025 is -$43,253,000.On average, 4 Wall Street analysts forecast MREO's earnings for 2025 to be -$29,812,554, with the lowest MREO earnings forecast at -$71,550,130, and the highest MREO earnings forecast at $63,600,116. On average, 3 Wall Street analysts forecast MREO's earnings for 2026 to be $0, with the lowest MREO earnings forecast at -$31,800,058, and the highest MREO earnings forecast at $55,650,101.

In 2027, MREO is forecast to generate -$3,975,007 in earnings, with the lowest earnings forecast at -$31,800,058 and the highest earnings forecast at $23,850,043.

What is MREO's revenue growth forecast for 2025-2027?

(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Mereo Biopharma Group's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast MREO's revenue for 2025 to be $66,382,620,574, with the lowest MREO revenue forecast at $39,750,072,200, and the highest MREO revenue forecast at $93,015,168,948. On average, 4 Wall Street analysts forecast MREO's revenue for 2026 to be $52,414,445,203, with the lowest MREO revenue forecast at $29,748,954,034, and the highest MREO revenue forecast at $74,173,634,725.

In 2027, MREO is forecast to generate $98,399,713,728 in revenue, with the lowest revenue forecast at $70,723,328,458 and the highest revenue forecast at $118,534,715,300.

What is MREO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MREO) forecast ROA is 187.33%, which is higher than the forecast US Biotechnology industry average of 35.52%.

What is MREO's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MREO price target, the average MREO price target is $7.60, with the highest MREO stock price forecast at $10.00 and the lowest MREO stock price forecast at $7.00.

On average, Wall Street analysts predict that Mereo Biopharma Group's share price could reach $7.60 by Apr 9, 2026. The average Mereo Biopharma Group stock price prediction forecasts a potential upside of 230.43% from the current MREO share price of $2.30.

What is MREO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MREO) Mereo Biopharma Group's current Earnings Per Share (EPS) is -$0.30. On average, analysts forecast that MREO's EPS will be -$0.04 for 2025, with the lowest EPS forecast at -$0.09, and the highest EPS forecast at $0.08. On average, analysts forecast that MREO's EPS will be $0.00 for 2026, with the lowest EPS forecast at -$0.04, and the highest EPS forecast at $0.07. In 2027, MREO's EPS is forecast to hit -$0.01 (min: -$0.04, max: $0.03).

What is MREO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MREO) forecast ROE is 234.71%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.